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Abstract 
Misfolded proteins of the secretory pathway are extracted from the endoplasmic reticulum 
(ER), polyubiquitylated by a protein complex termed the Hmg-CoA reductase degradation 
ligase (HRD-ligase) and degraded by cytosolic 26S proteasomes. The movement of these 
proteins through the lipid bilayer is assumed to occur via a protein conducting channel of 
unknown nature. We show that the integral membrane protein Der1 oligomerises which relies 
on its interaction with the scaffolding protein Usa1. Mutations in the transmembrane domains 
of Der1 block the passage of soluble proteins across the ER-membrane. As determined by 
site-specific photocrosslinking the ER-luminal exposed parts of Der1 are in spatial proximity 
to the substrate receptor Hrd3 whereas the membrane-embedded domains reside adjacent 
to the ubiquitin ligase Hrd1. Intriguingly, both regions also form crosslinks to client proteins. 
In summary our data imply that Der1 initiates the export of aberrant polypeptides from the 
ER-lumen by threading such molecules into the ER-membrane and routing them to Hrd1 for 
ubiquitylation. 
 
Introduction 
Folding of newly synthesised proteins in the secretory pathway is monitored by a quality 
control system that routes terminally aberrant polypeptides from the endoplasmic reticulum 
(ER) into the cytosol where they are polyubiquitylated and degraded by proteasomes. This 
process, termed ER-associated protein degradation (ERAD) 1, 2, is pivotal for the 
maintenance of cellular homeostasis and its mechanistic exploration will contribute to the 
treatment of various neurodegenerative disorders 3-5 and folding diseases like cystic fibrosis 
6, 7. Key components of ERAD are large multi-subunit ubiquitin ligases, which are embedded 
in the ER-membrane 8. In yeast the HRD-ligase promotes the degradation of soluble ER-
luminal as well as membrane-bound substrates. The core of this complex encompasses the 
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RING-finger type ubiquitin ligase Hrd1, which is integrated in the ER-membrane and exposes 
its catalytically active centre into the cytoplasm 9, 10. Hrd1 teams up with the substrate 
receptors Hrd3 and Yos9, which expose large soluble domains into the ER-lumen, and Usa1, 
which facilitates the assembly of the ligase complex 11-15. Intriguingly, another subunit Der1, 
an integral membrane protein with several transmembrane segments that is recruited to Hrd1 
via Usa1, is only required for the turnover of soluble but dispensable for the degradation of 
membrane-bound substrates 16-19. Because Der1 weakly binds client proteins it has been 
speculated that it either resembles a receptor for soluble targets or partakes in the 
dislocation of such polypeptides from the ER 12, 20. How aberrant proteins are exported from 
the ER in the course of ERAD is unknown. Remarkably, fully glycosylated and even partially 
folded ERAD substrates have been shown to traverse the ER-membrane prior to their 
degradation 21. This transport relies on the activity of the ubiquitin ligases and is generally 
believed to involve a proteinaceous channel 22-24. Several candidates for the constitution of 
such a dislocation apparatus have been discussed 25, 26. Here we report that the 
transmembrane domains of Der1 constitute a functional entity that is important for ERAD. 
Furthermore, soluble and membrane-embedded parts of Der1 are in spatial proximity to 
other components of the HRD-ligase and to dislocating substrate molecules. Our data imply 
that Der1 establishes a functional link between the selection of aberrant proteins in the ER-
lumen and their ubiquitylation in the cytoplasm by promoting the insertion of such 
polypeptides into the ER-membrane.  
 
Results 
Usa1-dependent integration of Der1 into the HRD-ligase promotes oligomerisation 
To assess possible functions of Der1 we were first interested on how this protein is 
integrated into the HRD-ligase protein complex. Usa1 links Der1 to Hrd1, which renders the 
ligase competent for the proteolysis of misfolded luminal ER proteins 14, 27. Sequence 
alignment of Der1 and its mammalian homologues, the Derlins, revealed an arrangement of 
conserved residues in the carboxyterminal region (GH179/180 and YY183/184; 
Supplementary Fig. 1a). The mutation of these residues specifically reduced the association 
with Usa1 as determined by co-immunoprecipitation experiments with Usa1-Myc (Fig. 1a and 
Supplementary table 1). Besides its linker function Usa1 also conveys the stability of Der1 14. 
Indeed, Der1 was degraded in a Hrd1- and Doa10-dependent manner in cells lacking Usa1 
(Supplementary Fig. 1b). Accordingly, the Usa1 binding-deficient Der1 mutants were 
unstable (Supplementary Fig. 1c). 
Der1 and other components of the HRD-ligase have been recently found to form oligomers 
14, 28. To determine, which factors contribute to this process we monitored the interaction of 
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Der1 equipped with a Myc-tag (Der1-Myc) and untagged Der1 in cells expressing both 
proteins and lacking individual components of the HRD-ligase. By precipitating Der1-Myc 
under native conditions we found that only the deletion of usa1 abrogated Der1-
oligomerisation (Fig. 1b). Mutations in the Usa1 interaction motif also caused the dissociation 
of Der1 oligomers (Fig. 1c). Importantly, Der1-Myc as well as co-expressed Der1 was stable 
in usa1-deleted cells, and thus a loss of oligomerisation cannot be explained by Der1 
instability (Supplementary Fig. 1d). A carboxyterminally HA-tagged version of Der1, which is 
instable in usa1-deleted cells, was also associated with co-expressed Der1 in a Usa1-
dependent manner (Supplementary Fig. 1e). However, overexpression of Der1, for example 
by inducing a cellular stress response pathway termed the unfolded protein response (UPR) 
by Dithiothreitol-treatment 29, 30, partially bypassed the requirement of Usa1 for 
oligomerisation (Fig. 1d). Therefore, Der1, similar to Hrd1 20, exhibits an intrinsic propensity 
to form oligomers. Under unstressed growth conditions, however, efficient oligomerisation of 
both proteins relies on their assembly by Usa1. 
 
Mutation of conserved residues in the transmembrane domains of Der1 block the 
dislocation of CPY* 
Der1 is predominantly involved in the turnover of misfolded ER-luminal proteins but it is 
unknown, how it contributes to this process 16, 17. Because Der1 binds client proteins even in 
the absence of the substrate receptor Hrd3 it was proposed that it constitutes a substrate 
recruitment factor of the HRD-ligase 12, 20, 31. However, the deletion of der1 already 
phenocopied the defect in the turnover of CPY*, a well established ER-luminal ERAD 
substrate, observed in hrd3- or hrd1-deleted cells and the combined deletion of der1 and 
hrd3 did not enhance this effect (Fig. 2a). In der1- and yos9-deleted cells we obtained a 
similar result (Fig. 2b). Moreover, the absence of Der1 could not be compensated by the 
simultaneous overexpression of Hrd1 and Hrd3 (Supplementary Fig. 2a). 
Immunoprecipitation experiments revealed that the amount of CPY* associated with the 
HRD-ligase was strongly reduced in absence of Hrd3, whereas it remained largely 
unchanged in der1-deleted cells (Fig. 2c, lane 11 and lane 10). Overall, these observations 
suggest a function of Der1 in line with rather than parallel to Hrd3/Yos9. 
On the basis of sequence similarity to rhomboid proteases Greenblatt et al proposed six 
transmembrane segments for the mammalian homologue Derlin-1 32. By contrast predictions 
based on hydrophobicity analysis as well as detailed biochemical studies support a topology 
of Der1 that comprises only four transmembrane domains 16. Nonetheless, the position of the 
transmembrane domains one and two is essentially the same in both models. We asked 
whether these segments are solely required for proper integration of Der1 into the HRD 
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ligase or whether they constitute a distinct functional entity for ERAD. Sequence alignment of 
yeast Der1 and its homologues from different organisms revealed conserved hydrophilic 
amino acids particularly in the first and second transmembrane domains (Supplementary Fig. 
1a). We changed some of these residues to alanine or leucine and monitored the effects on 
ERAD (Supplementary table 1). Mutations in the first transmembrane segment (R17L and 
C23L; Der1RC) moderately affected the turnover of the prevalent ERAD substrate CPY* (Fig. 
2d). A stronger defect was observed for the exchange of a conserved asparagine residue 
(N73L; Der1N) in the second transmembrane domain. The combination of R17L with N73L 
(Der1RN) caused a severe delay in CPY*-degradation. Notably, these mutations also stalled 
the turnover of PrA*, another well established soluble luminal ERAD substrate, whereas the 
degradation of 6xMyc-Hmg2, which relies on the HRD-ligase but does not require Der1 33, 
proceeded at similar rates in wild-type and Der1 mutant cells (Supplementary Fig. 2b). 
Mutations in the first luminal loop or in other regions of Der1 did not derogate ERAD 
(Supplementary Table 1). Der1N, Der1RN and Der1RC are stably expressed at levels 
comparable to the wild-type protein (Supplementary Fig. 2c). Moreover, as determined by 
immunoprecipitation the ability to form oligomers and the association with components of the 
HRD-ligase were not affected (Supplementary Fig. 2d and 2e).  
In cells deleted for der1 or expressing Der1RN we were unable to detect significant amounts 
of ubiquitylated CPY* (CPY*-Myc-Ub; Fig. 2e, lanes 10, 12). Because protein ubiquitylation is 
exclusively catalysed in the cytoplasm, the export of substrates from the ER appeared to be 
disturbed. Indeed, we found that most of CPY* was protected from Proteinase K treatment in 
lysates of these cells indicative for a localisation within a membrane bound compartment 
(Fig. 2f). By contrast, Der1RC cells contained low amounts of ubiquitylated CPY* and 
displayed a partial sensitivity of CPY* to Proteinase K corresponding to the milder 
degradation defect in this mutant (Fig. 2e, lane 11; Fig. 2f).  
 
Spatial proximity of Der1 to components of the HRD-ligase 
To get further insights in the function of the Der1 transmembrane domains we employed an 
in vivo site-specific photocrosslinking approach 34, 35. Der1-Myc was labelled in living cells 
with the photoreactive amino acid analogue p-Benzoylphenylalanine (pBpa) by 
overexpressing plasmid-encoded constructs that harbour a single amber stop codon at 
defined positions. The expression of a suppressor tRNA charged with pBpa allowed the 
incorporation of this crosslinker at the specified locations. Upon irradiation of cells with ultra 
violet (UV) light pBpa was activated and crosslinked to neighbouring proteins. Der1-Myc was 
then precipitated with anti-Myc antibodies from cell lysates and the samples were analysed 
by immunoblotting. We focussed our studies on positions in the transmembrane domains as 
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well as the first luminal loop of Der1 because these parts appeared to be most conserved. 
Notably, the overexpression of Der1 does not significantly interfere with the degradation of 
luminal substrates (Supplementary Fig. 3c) 14, 20. Furthermore, we conducted most of these 
experiments in cells expressing a catalytically inactive variant of the ERAD-specific ubiquitin 
conjugating enzyme Ubc7 (Ubc7C/S) to abrogate ERAD and thereby adjust the cellular 
levels of substrate molecules.  
We found prominent crosslinking products with Hrd1 at several positions in the 
aminoterminal part of the first and less intense crosslinks at few positions in the second 
transmembrane region of Der1 (Fig. 3; positions V25, S27, L29, S31, R33 and V35; F66, 
W68, I72 and F75). In cells lacking the Der1 adaptor Usa1 we were unable to detect such 
crosslinks demonstrating the specificity of the reaction (Fig. 4a). Crosslinks to Usa1 were 
almost exclusively observed for positions in the region around amino acids 146 to 152, which 
is consistent with the notion that the downstream part of Der1 is required for the binding to 
Usa1 (Fig. 3; positions I146, V148, P150 and I152). Surprisingly, we also detected major 
crosslinks to the putative substrate receptor Hrd3 predominantly for residues in the first ER-
luminal loop of Der1 (Fig. 3; positions G38, L46, K50 and Q52) whereas reactions to the 
Hrd3-associated lectin Yos9 were not found (Supplementary Fig. 3a). Again, the crosslinking 
reactions depended on the recruitment of Der1 to the HRD-ligase via Usa1 (Fig. 4b). A 
functional variant of Hrd3 that is deleted for the transmembrane region and only comprises 
the luminal domain (Hrd3 1-769) 12 also formed crosslinks with the pBpa-labelled Der1 
variants demonstrating a close spatial proximity between the luminal parts of both proteins 
(Fig. 4c). Some of the Der1-Hrd3 crosslinks involved residues that were calculated to map to 
the integral membrane domains of Der1 (Fig. 3; positions R33 and D62). Although we cannot 
formally rule out that the position of the transmembrane segments slightly differs from their 
predicted location, this indicated that the Hrd3 luminal domain is capable to immerge into the 
membrane-embedded part of Der1. By co-expressing pBpa-labelled Der1-Myc and 
unlabelled Der1-HA we detected crosslinking products of these proteins primarily for 
positions in the transmembrane regions (Fig. 4d). This finding confirms oligomer-formation of 
Der1 as suggested by the immunoprecipitation experiments and implies a tight association of 
the membrane-embedded segments within this assembly.  
Strikingly, pBpa-labelled Der1 could also be crosslinked to the ERAD substrate CPY*-HA. 
The most prominent crosslinks involved the luminal loop one and the luminally orientated 
parts of the Der1 transmembrane segments one, two and four (Fig. 3 and Supplementary 
Fig. 3b, e.g. positions R33, G38, K50, I60, D62 and I146). Position G38, which maps to the 
first ER-luminal loop of Der1, was of special interest because this residue appeared to be 
localised in close proximity to substrate as well as to the substrate receptor Hrd3. Unlabelled 
Der1-Myc did not form crosslinks with CPY*-HA or components of the HRD-ligase (Fig. 3; 
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outmost left lanes). Moreover, no crosslinks were detected when the UV-treatment was 
omitted. The modification of Der1 with pBpa did not affect the stability of the protein and had 
no significant effect on the activity of Der1 (Supplementary Fig. 3c). Furthermore, pBpa-
labelled Der1 variants were properly assembled into the HRD ligase as determined by the 
immunoprecipitation of selected constructs (Supplementary Fig. 3d). These results identified 
Der1 as a central factor in the HRD-ligase protein complex and implied that ER-luminal as 
well as membrane-embedded regions of Der1 reside in close contact to a soluble 
degradation substrate.  
 
Der1 directly binds substrate molecules 
Previous work indicated that Der1 exhibits a weak but specific substrate binding activity 12. 
We therefore wanted to determine the impact of the substrate receptor Hrd3 on the Der1-
CPY* crosslinks. To level out cellular protein amounts of CPY*-HA we conducted these 
experiments in Ubc7C/S cells (see above). The amount of CPY* that crosslinked to specific 
positions in the luminal loop of Der1 was substantially increased in the hrd3-deleted strain, 
which correlates to previous studies 31 (Fig. 5a). Likewise, the release of Der1 from the HRD-
ligase in cells lacking Usa1 mildly affected substrate crosslinking at positions in the luminal 
loop (Supplementary Fig. 4a). Notably, due to the overexpression of Der1 in the crosslinking 
setup the oligomeric state of the protein is still intact despite the deletion of usa1 
(Supplementary Fig. 4b, compare lanes 5 and 6). Consistently, substrate binding to Der1-
Myc or Der1-HA neither depended on Usa1 nor on Hrd3 as determined by 
immunoprecipitation in Ubc7C/S cells (Fig. 5b, compare lanes 6, 7 and 8; Supplementary 
Fig. 4c, compare lanes 5 and 6). To substantiate the specificity of the Der1-CPY* crosslinks 
we compared wild-type and ubiquitylation-deficient Ubc7C/S cells in the crosslinking 
experiments. The overall crosslinking pattern to Hrd1, Usa1 or Hrd3, which form a stable 
complex with Der1, was not affected by the activity of the ligase (Fig. 5c, Supplementary Fig. 
4d and 4e). However, the amount of crosslinking products was increased in Ubc7C/S cells 
possibly due to up-regulation of the HRD-ligase components by the UPR 30 (Supplementary 
Fig. 4f). In wild-type cells the amount of crosslinked CPY*-HA was clearly reduced albeit the 
relative intensity was almost identical for selected Der1 positions. This observation matched 
the idea that in the course of substrate processing no prevalent degradation intermediate of 
CPY*-HA accumulated at Der1. Intriguingly, this pattern was changed in the Ubc7C/S cells 
indicating that substrate molecules arrested in a particular constitution at the HRD-ligase 
(Fig. 5c). We also observed crosslinks of the ERAD substrate PrA*-HA to defined positions of 
Der1. The pattern of these crosslinks correlated with those observed for CPY*-HA 
suggesting that both substrates arrested in the same fashion at Der1 (Fig. 5d).  
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Importantly, pBpa-Der1-Myc could not be crosslinked to properly folded CPY-HA (Fig. 5e) or 
stable ER resident proteins like Kar2, an Hsp70-type ER-luminal chaperone 36, or Sec61, a 
membrane-bound component of the protein import apparatus 37 (Supplementary Fig. 4g) 
demonstrating that only proteins that are targeted for degradation by the HRD-ligase come 
into spatial proximity to Der1.  
 
Mutations in the Der1 transmembrane domains affect the crosslinking to HRD-ligase 
components and CPY*-3xHA 
In the following we employed the ERAD-deficient Der1RN mutant in the crosslinking 
experiments. Although this mutant protein appeared to be properly integrated into the HRD-
ligase as determined by immunoprecipitation, the amount of most crosslinking products with 
Hrd1, Usa1 and Hrd3 was significantly reduced indicating moderate structural changes in 
Der1 (Fig. 6a,b and Supplementary Fig. 5a). By contrast, the crosslinking products with 
CPY*-HA were increased predominantly at positions in the luminal loop of Der1 (Fig. 6a and 
6b, right panel, compare lanes 5 and 7). Noteworthy, the cellular level of this substrate 
remained unchanged (Supplementary Fig. 5b). Moreover, the individual pBpa-labelled Der1 
variants precipitated equal amounts of CPY*-HA, indicating that their ability to bind substrate 
molecules was not affected (Supplementary Fig. 5b). This strongly implied that ERAD 
substrates were unable to enter a dislocation complex in Der1RN cells, which in turn caused 
their accumulation at the luminal-exposed parts. Importantly, the crosslinking pattern of Der1 
and Der1RN to CPY*-HA was almost identical upon the release of these proteins from the 
HRD-ligase in cells deleted for usa1 (Fig. 6c, compare lanes 5 and 7 with Fig. 6a, lanes 5 
and 7). Thus, the accumulation of a particular degradation intermediate of CPY*-HA 
depended on the correct integration of Der1 into the HRD-ligase.  
 
Discussion 
Prior to their degradation misfolded proteins of the secretory pathway are routed from the ER 
into the cytoplasm. Intriguingly, these proteins are often modified by complex glycans, 
contain disulfide bridges and may be partially folded. This poses special requirements for the 
movement of such polypeptides through the ER-membrane. Previous work indicated that 
mammalian Derlin-1, a homologue of Der1, is involved in this process 38, 39. When 
overexpressed in mammalian cells, Derlin-1 and also the closely related Derlin-2 and -3 
proteins were shown to form oligomers, which are associated with ERAD ligases 40-42. 
Moreover, a protein complex containing Derlin-1 bound to client proteins before and after 
their extraction from the ER 38. Concordantly, the release of a model substrate from 
microsomes in a reconstituted system was efficiently inhibited by the addition of Derlin-1-
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specific antibodies 43. Although similar in size and topology Der1 and the Derlin proteins 
exhibit functional differences. The Derlins share certain amino acid motifs with inactive 
rhomboid proteases and contain a so-called SHP-box motif in their cytoplasmic 
carboxyterminal domain for direct binding to the AAA-ATPase p97, which are less conserved 
or not present in Der1 32. Moreover, the mammalian Derlin proteins are involved in the 
turnover of soluble and membrane-bound proteins, while Der1 is almost exclusively required 
for the degradation of soluble, ER-luminal substrates 38, 44, 45.  
Our data now provide strong evidence that yeast Der1 directly partakes in the extraction of 
aberrant proteins from the ER-lumen. First, upon Usa1-dependent assembly into the HRD-
ligase Der1 forms oligomers in the ER-membrane, which may be a prerequisite to enable the 
transit of substrate-proteins across a lipid layer. Second, the exchange of conserved polar 
residues in the transmembrane domains of Der1 abolishes export of polypeptides from the 
ER without affecting the overall topology of the HRD-ligase. Third, client proteins form 
crosslinks to ER-luminal as well as membrane-embedded parts of Der1 indicating that they 
are in close proximity to Der1 during dislocation from the ER. We are aware that the in vivo 
crosslinking approach allows the unspecific incorporation of pBpa into proteins that are 
naturally terminated by an amber stop-codon, which causes the production of abnormal 
species with carboxyterminal extensions. Still, we did not observe physiological alterations in 
pBpa-labelled cells and were unable to detect crosslinking products to unlabelled Der1-Myc. 
Fourth, the efficiency of pBpa-Der1 crosslinking to substrate molecules depends on the 
activity of the ligase and the assembly of Der1 into the ligase complex. And fifth, Der1 is 
located in the immediate vicinity of the substrate receptor Hrd3 as well as the ubiquitin ligase 
Hrd1 and is therefore at a prominent position to functionally link substrate selection in the 
ER-lumen with the ubiquitylating activity at the cytoplasmic face of the ER. 
Based on these observations we propose the following model for Der1 activity (Fig. 7). 
Malfolded proteins engage Hrd3 and Yos9 where they are selected for degradation. Those 
receptors then pass substrates to Der1, which acts downstream. Der1 contains regions in the 
ER-lumen that are in close proximity to Hrd3 and weakly bind aberrant polypeptides. This 
activity does not bypass the requirement for Hrd3 and Yos9 in ERAD. Rather, the access to 
Der1 appears to be restricted to client molecules that were pre-selected by Hrd3/Yos9. In the 
absence of Hrd3 Der1 probably binds polypeptides with low affinity, which does not suffice to 
trigger their degradation. Interestingly, mutations in the ER-luminal part of mammalian Derlin-
1 abolished its function in ERAD 32. We did not observe a similar effect for the corresponding 
positions in Der1 but we did not systematically investigate this issue. Next, Der1 initiates the 
insertion of substrate molecules into the ER-membrane. The assembly of multiple Der1 
subunits may generate a flexible funnel that supports immersion of even folded client 
proteins. Importantly, this step guides the substrates in spatial proximity to Hrd1 and 
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arranges them for ubiquitylation. The subsequent movement through the membrane may 
involve a proteinacious pore that contains Der1 and other proteins. Recently, the ubiquitin 
ligase Hrd1 has been implicated in the formation of such a conduit 14, 20. Hrd1 contains six 
transmembrane segments and also forms oligomers. While a mild 5-10 fold overexpression 
of Hrd1 failed to compensate for a loss of Der1 (Supplementary Figure 2a), strong 
overexpression of this protein partially substituted the function of Der1, Usa1, Hrd3 or Yos9 
20. Moreover, arrested dislocation intermediates could be crosslinked to Hrd1, which 
depended on the catalytic activity of the HRD-ligase 20. By contrast, crosslinks of substrates 
with Der1 were increased in a ubiquitylation deficient mutant. Since ubiquitylation was found 
to be mandatory for protein extraction from the ER this modification most likely prevents the 
dissociation of client proteins from Hrd1 and drives their export via the ubiquitin-dependent 
AAA-ATPase Cdc48/p97 46. Still, mutations in the Hrd1 transmembrane segments, which 
blocked the degradation of membrane-bound targets, had no impact on the turnover of 
soluble client proteins 47. Hence, further studies are needed to elucidate the detailed 
composition of the conduit that channels soluble ERAD substrates through the ER-
membrane.  
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Figure legends 
Figure 1 
The carboxyterminus of Der1 is required for oligomerisation and integration into the HRD-
ligase.  
a, Total cell extracts from Usa1-Myc Δder1 Δubc7 cells expressing various plasmid-encoded 
Der1 point mutants were solubilised with Digitonin and subjected to immunoprecipitation with 
antibodies against the Myc-epitope. The precipitates were analysed by SDS-PAGE and 
immunoblotting using specific antibodies. b, Der1-Myc was precipitated from cell lysates of 
yeast strains deleted for the given genes under non-denaturing conditions and the samples 
were analysed as described above. c, Yeast cells expressing Der1-Myc were transformed 
with plasmids encoding the given Der1 mutants. Der1-Myc was precipitated and the samples 
analysed as above. The asterisk denotes unspecific reactivity with the heavy chains of the 
antibody used in the immunoprecipitation. d, Yeast cells expressing Der1 and Der1-Myc 
were treated with 2 mM Dithiothreitol (DTT) for 2 hours to induce the unfolded protein 
response. Der1-Myc was then precipitated from cell lysates prepared under non-denaturing 
conditions and the samples were analysed as above. The asterisk denotes unspecific 
reactivity of the antibody as in c. 
 
Figure 2 
Mutations in the transmembrane domains of Der1 abolish the dislocation of luminal ERAD 
substrates.  
a,b, Pulse chase experiment to monitor CPY* turnover in the indicated yeast strains. Error 
bars represent standard deviation of three independent experiments. c, Microsomes were 
prepared from cells of the indicated genotype and solubilised with NP40. HA-tagged Hrd1 
was immunoprecipitated with anti-HA antibodies and the bound proteins were analysed by 
SDS-PAGE and immunoblotting. d, Graphical presentation of three independent experiments 
monitoring CPY* degradation in the indicated Der1 mutant strains by pulse chase analysis as 
in a. e, CPY*-Myc was immunoprecipitated from total cell lysates with anti-Myc antibodies. 
The precipitates were analysed by SDS-PAGE and immunoblotting using anti-ubiquitin 
antibodies. Rpt4R refers to a yeast strain expressing a dysfunctional version of the 
proteasomal AAA-ATPase Rpt4, which causes the accumulation of ubiquitylated proteins. 
The asterisk denotes unspecific reactivity with the heavy chains of the antibody used in the 
immunoprecipitation. f, Protease-protection assay to monitor the export of CPY* from the ER. 
Cells of the indicated genotypes were incubated with cycloheximide for 1 hour and lysed 
under conditions that allowed the formation of vesicles (see Methods). The samples were 
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treated with Proteinase K and Triton-X 100 or left untreated. Proteins were precipitated and 
analysed by SDS-PAGE. Immunoblotting with anti-Kar2 antibodies serves as control for the 
integrity of the vesicles. The processing of the ER luminal protein Kar2 to a protease-
resistant fragment (*) in absence of Triton-X 100 indicates a leakage of some vesicles. 
 
Figure 3 
pBpa-labelled Der1 forms crosslinks with components of the HRD-ligase.  
Yeast cells deleted for der1 and expressing HA-tagged CPY* as well as catalytically inactive 
Ubc7 (Δder1 CPY*-HA Ubc7C/S) were transformed with high-copy plasmids encoding Der1-
Myc variants controlled by the CUP promoter and containing the photoreactive amino acid 
analogue pBpa at the indicated positions (derived from pMM075). To determine the 
specificity of the crosslinking reaction the experiment was performed with an unmodified 
version of Der1-Myc (wt) (pMM075). After UV irradiation the cells were lysed and Der1-Myc 
was immunoprecipitated. Proteins crosslinked to pBpa-labelled Der1 were detected by 
immunoblotting with specific antibodies. The relative position of the Der1 transmembrane 
segments according to Hitt et al. 16 is given by green bars (see also Supplementary Figure 
1a). 
 
Figure 4 
The pBpa-labelled Der1 variants are properly integrated into the HRD-ligase.  
a, Der1-Myc constructs (derived from pMM075) containing photoreactive probes at positions 
which show prominent crosslinks with Hrd1 were expressed in Δder1 Ubc7C/S CPY*-HA 
cells lacking Usa1 where indicated and subjected to in vivo photocrosslinking as described 
(see Methods). The asterisks mark signals that cross-react with the anti-Myc antibody. b, As 
in a but the photoreactive probes were placed at positions which were found to display 
intense crosslinks with Hrd3.c, As in abut the labelled Der1-Myc constructs were transformed 
into Δder1 cells that either express full length Hrd3 or the luminal domain of Hrd3 (1-767).d, 
Δder1 Ubc7C/S cells were transformed with pBpa-labelled Der1-Myc constructs (derived 
from pMM075) and a high-copy number plasmid encoding Der1-HA (pMM079). Upon UV 
irradiation and cell lysis Der1-Myc was precipitated and crosslinks to Der1-HA were detected 
by anti-HA antibodies via immunoblotting. 
 
Figure 5 
pBpa-Der1 crosslinks to luminal ERAD substrates.  
a, Der1-Myc labelled with pBpa at positions in the first luminal loop (G38, Y42) and in the 
second transmembrane region (S70) (derived from pMM075) were expressed in Δder1 
CPY*-HA Ubc7C/S cells that lacked Hrd3 where indicated. After UV irradiation Der1-Myc 
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was immunoprecipitated from cell lysates and analysed as in Figure 3. The asterisks mark 
signals that cross-react with the antibodies. b, Microsomes from cells of the indicated 
genotype were solubilized with NP-40 and Der1-Myc was precipitated with anti-Myc 
antibodies. To adjust the cellular levels of substrate molecules the experiment was 
performed in cells deleted for ubc7 (lanes 4 and 8) or expressing a catalytically inactive 
mutant of this enzyme (Ubc7C/S) (lanes 1-3 and 5-7). c, As in a but Der1-Myc was either 
expressed in Δder1 CPY*-HA cells (wt) or in Δder1 CPY*-HA Ubc7C/S cells. d, Δubc7 cells 
expressing either properly folded CPY-HA (wt) or the misfolded variant (mut) were 
transformed with Der1-Myc constructs that incorporated the photoreactive crosslinker pBpa 
at positions in the first luminal loop (G38) and in the second transmembrane domain (D62, 
S70) (derived from pMM075). The crosslinking experiment was performed as in a. The signal 
intensity of CPY-HA in the input lanes was reduced compared to CPY*-HA due to vacuolar 
processing of the HA-epitope. e, Der1-Myc labelled with pBpa at positions in the first (R33), 
second (D62, F66, S70) or fourth (I146) transmembrane domain or in the first luminal loop 
(G38) (derived from pMM075) were expressed in Ubc7C/S cells that lacked endogenous 
Proteinase A (Δpep4) and contained a low-copy plasmid encoding PrA*-HA (pMM076). By 
using an unlabelled version of Der1-Myc (pMM075) the specificity of the crosslinking reaction 
was determined. The crosslinking experiment was performed as in a.  
 
Figure 6 
Dislocation deficient point mutants of Der1 affect the crosslinking to HRD-ligase components 
and CPY*-HA.  
a, Δder1 Ubc7C/S CPY*-HA cells were transformed with high-copy plasmids encoding either 
Der1-Myc (derived from pMM075) or Der1RN-Myc (derived from pMM074) which contain 
photoreactive probes in the first (S31) and fourth (I146) transmembrane domain or in the first 
luminal loop (G38). Upon UV irradiation and cell lysis, the Der1-Myc variants were subjected 
to immunoprecipitation with anti-Myc antibodies. The crosslinked interaction partners were 
analysed by SDS-PAGE and immunoblotting using specific antibodies. b, Positions which 
show significant crosslinks with Hrd1 (left panel) or Hrd3 (right panel) were modified with 
pBpa in Der1-Myc and Der1RN-Myc, respectively. The Der1 constructs were expressed in 
Δder1 Ubc7C/S CPY*-HA cells and pBpa was activated by UV light. c, As in a but the Der1-
Myc variants were expressed in Δder1 Ubc7C/S CPY*-HA cells that were deleted for usa1. 
 
Figure 7 
A model for the function of Der1 in the dislocation of ERAD substrates. 
Misfolded ER-luminal proteins (red) are bound by the receptors Hrd3 and Yos9 (blue) in the 
ER-lumen. Selected substrate molecules are then transferred to Der1 (green). Der1 weakly 
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binds aberrant polypeptides via its ER-luminal exposed parts that are shielded by Hrd3 in the 
assembled ligase complex. The association with Der1 initiates the insertion of the substrates 
into the ER-membrane. Notably, the transmembrane domains of Der1 appear to be important 
for this process. Subsequently the substrate molecules are routed to the ubiquitin ligase Hrd1 
(orange) for ubiquitylation. This modification stabilises the association of substrates with the 
HRD-ligase and triggers their dislocation from the ER. Complete movement of client proteins 
through the ER-membrane most likely occurs via a conduit containing the transmembrane 
segments of Der1 and Hrd1 and depends on the activity of the ubiquitin-specific AAA-
ATPase Cdc48 (not shown). 
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Methods 
Antibodies 
Monoclonal anti-HA (H9658, Sigma-Aldrich, St. Louis, USA; C29F4, NEB, UK) and anti-Myc 
(M5546, Sigma-Aldrich, St. Louis, USA) antibodies used for immunoprecipitation (dilution 
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1:2,000) and detection (dilution 1:2,500 – 1:5,000) were commercially available. Antibodies 
for immunodetection of Hrd1 (1:10,000), Hrd3 (1:3,000), Sec61 (1:10,000), Der1 (1:500) and 
Usa1 (1:3,000) were described previously 12, 14. Antibodies for immunodetection of Kar2 
(1:10,000) and Pep4 (1:3,000) were a generous gift from T.A. Rapoport and D.H. Wolf, 
respectively. The monoclonal antibody directed against CPY (A-6428; used 1:2,500 for 
immunoprecipitation and 1:5,000 for immunodetection) was purchased from Molecular 
Probes. Fluorescently labelled secondary antibodies (IRDye 800, anti-mouse IgG (goat) and 
IRDye 800, anti-rabbit (goat); each used 1:2,000 for immunotecetion by LiCor) were 
purchased from Rockland. The polyclonal anti-Yos9 antibody was generated by immunising 
rabbits with a fragment of Yos9 purified from E. coli and used at a dilution of 1:2,000 for 
immunodetection. The polyubiquitin-specific antibody (UG9510, Enzo Life Science) was 
diluted 1:2,000 in immunoblotting. Horseradish-peroxidase coupled secondary antibodies 
(A9044 and A0545; both diluted 1:10,000) used for immunodetection of proteins by 
Enhanced Chemiluminiscence were purchased from Sigma-Aldrich, St. Louis. 
 
Yeast strains and plasmids 
For yeast sporulation, tetrad dissection and the preparation of yeast media standard 
protocols were used 48. The genotypes of yeast strains are listed in the Supplementary Table 
2. These strains are derived from the diploid wild-type strain DF5. Described methods were 
followed for the deletion and chromosomal epitope tagging of genes in yeast 49, 50. DNA-
plasmids used in this study are summarised in the Supplementary Table 3. Overall, a DNA 
fragment was PCR-amplified with oligonucleotides that are flanked by suitable restriction 
sites and inserted into appropriate vectors. The modification of plasmid-encoded genes with 
epitopes (pMM074, pMM075 and pMM076) was done by expressing these constructs in the 
respective deletion strains and homologues recombination of an appropriate DNA-cassette 
as described 50. Der1 constructs containing point mutations were generated by QuikChange 
site-directed mutagenesis using Pfu High Fidelity DNA-polymerase according to the 
manufacturer’s instructions (Agilent Technologies, USA). For the generation of constructs 
that express p-Benzoylphenylalanine- (pBpa-) labelled Der1 variants pMM074, pMM075 and 
pMM063 were used as parental plasmids. The stop codon TAG was introduced at individual 
positions by site-directed mutagenesis as described above. pMM001, pMM040 and pMM041 
were used for the insertion of point mutations into the chromosomal locus of Der1 leading to 
YMM156, YMM111 and YMM112. 6xMyc-Hmg2 was expressed from plasmid pRH244 as 
described elsewhere 33. pJU293 and pJU294 are 2µm-based multicopy plasmids that contain 
combinations of the genes HRD1, HRD3 and DER1 under the control of their respective 
promoters (around 400 bp of the 5’ non-coding sequence).  
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Native immunoprecipitation 
50 OD600 yeast cells in early logarithmic phase were harvested and lysed by vigorous 
shaking with glass beads in ice-cold lysis buffer (50 mM Tris-HCl (pH 7.5), 400 mM KOAc, 
0,5 mM EDTA, 10 % (v/v) Glycerol, 1 mM phenymethyl sulphonyl fluoride (PMSF)). The cell 
debris was removed by low-speed centrifugation (2,000 x g, 3 min). The supernatant was 
supplemented with 1 % (w/v) Digitonin (Calbiochem, USA) and incubated for 1 hour under 
rotation at 4 °C. The lysate was cleared by high-speed centrifugation at 20,800 x g for 20 min 
and diluted with lysis buffer to a final concentration of 0.5 % (w/v) Digitonin. For 
immunoprecipitation specific antibodies and Protein A-conjugated Sepharose were added. 
Bound proteins were eluted with dithiothreitol (DTT) containing sample buffer and analysed 
by Sodiumdodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. For 
the immunoprecipitation of CPY* the protocol was modified. 150 OD600 yeast cells were 
harvested and lysed in IP32-buffer (50 mM HEPES (pH 7.5), 50 mM NaCl, 125 mM KOAc, 2 
mM MgOAc2, 1 mM EDTA, 10 µM CaCl2, 3 % (v/v) Glycerol). Next, microsomes were 
collected by high-speed centrifugation (20,800 x g, 20 min) and solubilised with 0.5 % (v/v) 
Nonidet P40. The following steps were performed as described above. 
 
Determination of protein degradation 
The turnover of proteins were either analysed by pulse chase experiments or cycloheximide 
decay assays as described elsewhere 51-53. Briefly, for pulse chase analysis yeast cells were 
pulsed with radiolabelled 35S methionine followed by a chase with an excess of unlabelled 
amino acids. During the chase samples were taken at indicated time points and mixed with 
NaN3. The cells were lysed under denaturing conditions and the protein of interest was 
immunoprecipitated with specific antibodies. For the analysis of CPY* or PrA* the bound 
proteins were treated with Endoglycosidase F. The samples were then separated by SDS-
PAGE followed by autoradiography using a PhosphoImager (Typhoon FLA9500, GE 
Healthcare).  
For a cycloheximide decay assay yeast cells were incubated with 0.3 mg/ml cycloheximid in 
order to stop protein synthesis. Samples were collected at indicated time points and the cells 
were lysed with glass beads in buffer containing 50 mM Tris-HCl [pH 7.5], 10 mM EDTA, 1 
mM PMSF. Microsomes were recovered by high-speed centrifugation (20,800 x g, 20 min) 
and suspended in sample buffer. The analysis of the samples was carried out by SDS-PAGE 
and immunoblotting. 
 
Detection of ubiquitylated CPY* 
150 OD600 yeast cells were harvested and washed with 20 mM N-ethylmaleimide (NEM), 10 
mM NaN3 and 1 mM PMSF. After lysis of the cells with glass beads in Ub-buffer (0.7 M 
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sorbitol, 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1 % (v/v) Triton-X 100, 0,1 % 
(w/v) SDS) supplemented with 20 mM NEM and 1 mM PMSF the cell extract was incubated 
for 1 hour for efficient solubilisation of membranes. Insoluble material was then cleared from 
the lysate (20,800 x g, 20 min). Subsequently, CPY*-Myc was precipitated with anti-Myc 
antibodies. Bound proteins were eluted by DTT containing sample buffer and analysed by 
SDS-PAGE and immunoblotting. Ubiquitylated CPY*-Myc was detected by specific anti-
ubiquitin antibodies. 
 
Site-specific in vivo photocrosslinking 
Yeast cells were transformed with pGK1-pBpa (a generous gift from P.G. Schultz) and Der1-
Myc constructs derived from pMM074 or pMM075 containing an amber stop codon at 
specific positions 34, 35. Transformed yeast cells were grown in synthetic minimal medium 
supplemented with 400 µM pBpa (Bachem, CH) over night at 30 °C. The expression of Der1-
Myc was induced by addition of 0.1 mM CuSO4 for 2 hours. 150 OD600 yeast cells were 
harvested and washed twice with ice-cold H2O. Next, the cells were suspended in 2 ml H2O, 
transferred to a 6-well plate and irradiated with UV light (B-100AP, UVP, CA) at λ = 365 nm 
for 45 min on ice. The cells were lysed with glass beads in 50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 5 mM EDTA, 1 % (v/v) Triton X-100, 0.1 % (w/v) SDS, 1 mM PMSF. The lysate was 
cleared from cell debris and the microsomes were solubilised as described above. Insoluble 
material was removed by high-speed centrifugation (20,800 x g, 20 min) and Der1-Myc was 
immunoprecipitated with anti-Myc antibodies. Bound proteins were eluted with DTT-
containing sample-buffer and analysed by SDS-PAGE and immunoblotting. For quantification 
of the crosslinking efficiency immunoblots were incubated with fluorescently labelled 
secondary antibodies and analysed by the Odyssey near-infrared Imaging System (Li-Cor). 
 
Protease protection assay 
To monitor the dislocation of a CPY fraction from the ER over a time period of 1 hour the 
protein synthesis in yeast cells was inhibited by addition of cycloheximide as described 
before. Samples were collected at the indicated time points and washed with 10 mM NaN3. 
To keep the membranes intact the cells were lysed in sorbitol-buffer (0.7 M sorbitol, 50 mM 
Tris-HCl (pH 7.5)). Afterwards, the lysate was cleared from cell debris and treated with 0.1 
mg/ml proteinase K, or proteinase K in presence of 0.5 % (v/v) Triton-X 100 for 20 min on 
ice. The reaction was stopped by the addition of 1 mM PMSF and 15 % (w/v) trichloro-acetic 
acid. The proteins were then recovered by high-speed centrifugation (20,800 x g, 20 min) 
and dissolved in sample buffer (pH 8) before analysis by SDS-PAGE and immunoblotting. 
 
ß-galactosidase activity assay 
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For the measurement of UPR induction yeast cells were transformed with a UPR-induced 
reporter construct (pUPRE-lacZ). The ß-galactosidase activity was determined as previously 
described 29. 
 
Reproducability of experiments 
All data are representative of at least three independent experiments with the exception of 
Figures 1c (two independent experiments), Supplementary Figures 1c, 1e, 2b right panel, 2c, 
3a, 3c, 4c and 5a (two independent experiments each) and Supplementary Fig. 3b (one 
experiment). Uncropped images of key experiments can be seen in Supplementary Fig. 6.  
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Supplementary material 
Supplementary Figure 1 
The carboxyterminus integrates Der1 into the HRD-ligase  
a, Sequence alignment of yeast Der1 with homologues in other organisms, generated by 
ClustalW and Jalview. Derlin-1 from Homo sapiens (hs, UniProtKB accession number 
Q9BUN8), Caenorhabditis elegans (ce, Q93561), Derlin-2 from Homo sapiens (hs, 
Q9GZP9), Caenorhabditis elegans (ce, Q21997), Derlin-3 from Homo sapiens (hs, Q96Q80), 
Mus Musculus (mm, Q9D8K3), Der1 from Saccharomyces cerevisiae (sc, P38307). The 
position of the Der1 transmembrane segments as predicted by hydrophobicity calculations 
and biochemical analysis by Hitt et al. 16 is given by green bars. Of note, in an alternative 
model for Derlin-1 topology proposed by Greenblatt et al. 32, the position of transmembrane 
segments one and two is almost identical. Black diamonds label amino acids in Der1, which 
were subjected to site-directed mutagenesis (Supplementary Table S1). b, Cycloheximide 
decay assay to monitor the degradation of Der1 in strains of the indicated genotypes. c, As in 
b but Δder1 cells were transformed with low-copy number plasmids encoding mutants of 
Der1. d, Cycloheximide decay decay assay to determine turnover of Der1-Myc and Der1 in 
Δusa1 cells. The integral ER-membrane protein Sec61 served as loading control. e, Plasmid-
encoded HA-tagged Der1 was expressed with endogenous Der1 in cells containing or 
lacking Usa1. Membranes of the total extract were solubilised with Digitonin and Der1-HA 
was precipitated with anti-HA antibodies followed by SDS-PAGE and immunoblotting. 
 
Supplementary Figure 2 
Characterisation of the dislocation deficient Der1 transmembrane mutants.  
a, Wt and Δder1 cells were transformed with high-copy plasmids encoding HRD1 and HRD3 
(pJU293) or HRD1, HRD3 and DER1 (pJU294). The turnover of CPY* was determined by 
radioactive pulse chase analysis and the results quantified using a PhosphoImager.b, Pulse 
chase experiment to analyse the effect of the Der1 transmembrane mutants on the 
degradation of PrA* (left panel) and 6xMyc-Hmg2 (right panel). Error bars represent the 
standard deviation of three independent experiments. c, Cycloheximide decay assay to 
monitor the stability of the Der1 transmembrane mutants. The asterisk denotes a loss of cell 
material during the sample preparation.d, Digitonin-solubilised lysates from cells expressing 
Usa1-Myc and the indicated Der1 variants were subjected to immunoprecipitation with anti-
Myc antibodies (left panel). Vice versa cells expressing the indicated variants of Der1-Myc 
were lysed and tested for interaction to different components of the HRD-ligase by 
immunoprecipitation with anti-Myc antibodies (right panel). The bound proteins were 
analysed by SDS-PAGE and immunoblotting using specific antibodies.e, Cells expressing 
Der1-Myc were transformed with low-copy number plasmids encoding either Der1 or Der1 
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transmembrane mutants were lysed in Digitonin buffer and subjected to precipitation with 
anti-Myc antibodies. 
 
Supplementary Figure 3 
The pBpa-labelled Der1 variants are properly integrated into the HRD-ligase.  
a, Der1-Myc labelled at positions in the first (W19) and second (S70) transmembrane domain 
as well as in the first luminal loop (G38, Y42, L46, K50) (derived from pMM075) were 
expressed in Δder1 Ubc7 C/S CPY*-HA cells to investigate crosslinking to Yos9.b, Efficiency 
of the CPY*-HA crosslinking to different positions in Der1-Myc. Photoreactive probes were 
introduced at the indicated positions of Der1-Myc (derived from pMM075) and the 
crosslinking experiment was performed as described (see Methods). Crosslinked CPY*-HA 
and precipitated pBpa-labelled Der1-Myc were detected by fluorescently labelled secondary 
antibodies using the Odyssey near-infrared scanner (Li-Cor) and quantified by Odyssey 
Imaging System Version 3.0. The amount of the CPY*-HA crosslinking at position G38 was 
set to 100 %. The efficiency of the CPY*-HA crosslinking at other positions was calculated in 
relation to position G38 and normalised by the corresponding precipitated pBpa-labelled 
Der1-Myc variant. The asterisk denotes a cross-reactivity of the anti-Myc antibody.c, Pulse 
chase assay to analyse the activity of pBpa-modified Der1 variants in the degradation of 
CPY*. The selected Der1 constructs (derived from pMM063) form prominent crosslinks with 
different components of the HRD ligase as well as CPY*-HA and were expressed on high-
copy plasmids in Δder1 cells. As a control unlabelled Der1 was expressed on a low-copy (wt) 
and high-copy plasmid (Der1 OE), respectively.d, Δder1 Ubc7C/S CPY*-HA cells expressing 
either various pBpa-labelled Der1-Myc constructs or unlabelled Der1-Myc were lysed in 
Digitonin containing buffer and subjected to immunoprecipitation with anti-Myc antibodies. 
Interaction partners of Der1-Myc were analysed by SDS-PAGE and immunoblotting. The 
asterisk denotes a cross-reactivity of the anti-Hrd1 antibody in the total lysate. 
 
Supplementary Figure 4 
Der1 is in close proximity to dislocated CPY*.  
a, Photoreactive probes were placed at the indicated positions in Der1-Myc. The constructs 
were expressed in Δder1 Ubc7C/S CPY*-HA cells either containing or lacking Usa1 and 
exposed to UV light. The samples were then lysed and subjected to immunoprecipitation as 
described in Figure 3. b, Der1-HA expressed from high-copy plasmid pMM079 was 
transformed into Δder1 Ubc7C/S cells either containing or lacking Usa1. Der1-Myc labelled 
with pBpa at position G38 (derived from pMM075) was co-expressed where indicated. Cells 
were lysed in Digitonin containing buffer and Der1-Myc was immunoprecipitated with anti-
Myc antibodies. Interacting Der1-HA was detected by immunoblotting. c, Δder1 Ubc7C/S 
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cells were transformed with a low-copy plasmid encoding Der1-HA. Microsomes of these 
cells were solubilised with NP40 and Der1-HA was precipitated with anti-HA antibodies. The 
catalytically inactive Ubc7 mutant (Ubc7C/S) was used to adjust the substrate levels in the 
individual strains. d, Der1-Myc constructs with photoreactive probes placed at positions 
which reveal prominent crosslinks with Hrd1 were expressed either in Δder1 CPY*-HA cells 
(wt) or in Δder1 CPY*-HA Ubc7C/S cells. The photocrosslinking was performed as described. 
e, As in d but the Der1-Myc constructs contained photoreactive probes at positions, which 
formed crosslinks with Usa1. f, Determination of the unfolded protein response (UPR) in 
strains used for the crosslinking experiments by ß-galactosidase activity assay. The indicated 
yeast strains were transformed with the pUPRE-lacZ plasmid and the activity of ß-
galactosidase was measured as described (see Methods). Where indicated cells were 
treated with 4 mM Dithiotriol (DTT) for 1 hour before ß-galactosidase measurement to fully 
induce the UPR. Error bars and mean values of three independent experiments are shown. 
g, Der1-Myc variants labelled at the indicated positions were expressed in Δpep4 Ubc7C/S 
cells containing plasmid-encoded PrA*-HA. The crosslinking experiment was performed as in 
a. 
 
Supplementary Figure 5 
The pBpa-labelled Der1RN-Myc transmembrane mutant is properly assembled with the 
HRD-ligase but displays alterations in the crosslinking to its interaction partners.  
a, Δder1 Ubc7C/S CPY*-HA cells were transformed with high-copy plasmids encoding either 
pBpa-modified Der1-Myc (derived from pMM075), Der1RN-Myc (derived from pMM074) or 
unlabelled Der1-Myc (pMM075). Digitonin-solubilised membranes of the total extract were 
subjected to immunoprecipitation with anti-Myc antibodies (left and right panel). b, As in a but 
the microsomes were solubilised with NP40 before precipitation of the Der1-Myc constructs. 
 
Supplementary Figure 6 
Full gel scans of key blots shown in the main figures of this manuscript. Antibodies used for 
protein detection are indicated. 
 
Supplementary Table 1 
Characterisation of Der1 mutants generated by site-directed mutagenesis.  
The indicated amino acids in Der1 were changed to alanine (A), leucine (L) or tryptophan (W) 
and analysed for their stability and their ability to promote CPY* degradation by 
cycloheximide decay assay. The interaction to Usa1 and the ability to form oligomers were 
determined by immunoprecipitation. Der1 transmembrane mutants deficient for CPY* 
degradation and used for following experiments are highlighted in red. 
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Supplementary Table 2 
Yeast strains used in this study 
 
Supplementary Table 3 
Plasmid constructs used in this study 
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Supplementary Table 1 (Jarosch) 
Amino acid Der1 stability 
CPY* 
degradation 
Usa1 
interaction 
Der1 
oligomerisation 
T16A + + n.d. n.d. 
R17L + - + + 
C23L + - + + 
P37A + + n.d. n.d. 
G38W + + n.d. n.d. 
D45A + + n.d. n.d. 
L46A + + n.d. n.d. 
K49A + + n.d. n.d. 
K50A + + n.d. n.d. 
Q52A + + n.d. n.d. 
R55A + + n.d. n.d. 
Y58L + + n.d. n.d. 
S59L - - - - n.d. n.d. 
S70A + + n.d. n.d. 
N73L + - + + 
S77L + + n.d. n.d. 
LEN84-
86AAA - - - - + + 
R91A + + n.d. n.d. 
Y128A + + n.d. n.d. 
P154A + + n.d. n.d. 
GH179/180LA - - - - - - - - 
YY183/184AA - - - - 
DD186/187AA + + + + 
P201A + + + + 
	  
Supplementary Table 2 (Jarosch) 
Yeast strain Genotype Reference 
DF5 trp1-1 (am)/ trp1-1 (am), his3-Δ200/ his3-Δ200, ura3-52/ ura3-52, lys2-801/ lys2-801, leu2-3, -112/ leu2-3, -
112, MATα/a 
1 
YBM70 Δhrd3::LEU2, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATα 2 
YJU32 Δder1::HIS3, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 3 
YJU37 Δhrd1::TRP1, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 3 
YMM010 Δhrd1::LEU2, Δdoa10::HIS3, Δusa1::KanMX6, prc1-1, MAT n.d. this study 
YMM012 Δdoa10::HIS3, Δusa1::KanMX6, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MAT n.d. this study 
YMM060 usa1-3xMyc:KanMX6, Δder1::HIS3, Δubc7::LEU2, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-
3, -112, MAT n.d. 
this study 
YMM111 der1 R17L N73L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM112 der1 R17L C23L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM118 der1 R17L C23L-13xMyc:HIS3, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM119 der1 R17L N73L-13xMyc:HIS3, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM132 usa1-3xMyc:KanMX6, der1 N73L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM133 usa1-3xMyc:KanMX6, der1 R17L C23L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, 
MATa 
this study 
YMM134 usa1-3xMyc:KanMX6, der1 R17L N73L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, 
MATa 
this study 
YMM138 prc1-1-13xMyc:TRP1, der1 R17L C23L, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM139 prc1-1-13xMyc:TRP1, der1 R17L N73L, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM140 6xMyc-hmg2:URA3, der1 N73L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM141 6xmyc-hmg2:URA3, der1 R17L C23L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, 
MATa 
this study 
YMM142 6xMyc-hmg2:URA3, der1 R17L N73L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, 
MATa 
this study 
YMM143 Δpep4::URA3, der1 N73L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM144 Δpep4::URA3, der1 R17L C23L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM145 Δpep4::URA3, der1 R17L N73L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM156 der1 N73L, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM157 ubc7 C89S, Δder1::HIS3, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM158 ubc7 C89S, Δder1::HIS3, prc1-1-3xHA:KanMX6, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, 
MATa 
this study 
YMM179 der1-13xMyc:TRP1, Δusa1::HIS3, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MAT n.d. this study 
YMM187 Δder1::HIS3, Δhrd3::LEU2, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM190 ubc7 C89S, Δder1::HIS3, Δhrd3::TRP1, prc1-1-3xHA:KanMX6, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, 
leu2-3, -112, MATa 
this study 
YMM191 Δder1::HIS3, ubc7 C89S, Δusa1::TRP1, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, 
MAT n.d. 
this study 
YMM199 Δder1::HIS3, ubc7 C89S, prc1-1-3xHA:KanMX6, Δusa1::TRP1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, 
leu2-3, -112, MATa 
this study 
YMM200 hrd1-3xHA:HIS3, ubc7 C89S, Δder1::TRP1, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -
112, MAT n.d. 
this study 
YMM201 hrd1-3xHA:HIS3, ubc7 C89S, Δhrd3::LEU2, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -
112, MAT n.d. 
this study 
YMM202 hrd1-3xHA:HIS3, ubc7 C89S, Δder1::TRP1, Δhrd3::LEU2, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-
801, leu2-3, -112, MAT n.d. 
this study 
YMM203 der1 N73L-13xMyc:TRP1, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YMM204 ubc7 C89S, Δpep4::KanMX6, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
YRG184 Δder1::HIS3, hrd3 (1-769):KanMX6, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 4 
YSH029 Δusa1::TRP1, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 5 
YSH061 der1-13xMyc:TRP1, Δusa1::KanMX6, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, 
MATa 
5 
YTX140 prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 1 
YTX372 der1-13xMyc:KanMX6, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 4 
YTX378 der1-13xMyc:KanMX6, Δhrd1::TRP1, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, 
MATa 
4 
YTX380 hrd1-3xHA:KanMX6, ubc7 C89S, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 4 
YTX404 Δder1::HIS3, prc1-1-3xHA, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MAT n.d. this study 
YTX481 der1-13xMyc:KanMX6, Δhrd3::LEU2, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, 
MATα 
this study 
YTX539 der1-13xMyc:KanMX6, Δubx2::TRP1, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, 
MATa 
this study 
YTX625 usa1-3xMyc:KanMX6, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATα 5 
YTX645 Δusa1::TRP1, Δhrd1::LEU2, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATα this study 
YTX740 6xMyc-hmg2:URA3, Δhrd1::TRP1, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 5 
YTX742 6xMyc-hmg2:URA3, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 5 
YTX817 prc1-1-13xMyc:TRP1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 5 
YTX822 prc1-1-13xMyc:TRP1, Δder1::HIS3, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 5 
YTX836 Δpep4::URA3, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 5 
YTX837 Δpep4::URA3, Δder1::HIS3, prc1-1, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa 5 
YTX865 prc1-1-13xMyc:TRP1, rpt4R, trp1-1 (am), his3-Δ200, ura3-52, lys2-801, leu2-3, -112, MATa this study 
 
MAT n.d. Mating type not determined 
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Supplementary Table 3 (Jarosch) 
Plasmid Plasmid backbone Description Reference 
pTX339 pRS415 PrA* 1 
pGK1-pBpa  3SUP4-tRNACUA for pBpa incorporation 2 
pRH244  6xMyc-Hmg2 for genomic integration 3 
pTX227 pRS416 Der1 -499/+728 this study 
pTX228 pTX227 Der1 (R17L) this study 
pTX230 pTX227 Der1 (C23L) this study 
pTX231 pTX227 Der1 (N73L) this study 
pMM001 pRS406 Der1 -499/+728 (N73L) this study 
pMM012 pTX227 Der1 (T16A) this study 
pMM013 pTX227 Der1 (S70A) this study 
pMM014 pTX227 Der1 (LEN84-86AAA) this study 
pMM015 pTX227 Der1 (R91A) this study 
pMM016 pTX227 Der1 (Y128A) this study 
pMM017 pTX227 Der1 (P154A) this study 
pMM020 pTX227 Der1 (GH179LA) this study 
pMM021 pTX227 Der1 (YY183AA) this study 
pMM022 pTX227 Der1 (DD186AA) this study 
pMM023 pTX227 Der1 (P201A) this study 
pMM040 pRS406 Der1 -499/+728 (R17LC23LN73L) this study 
pMM041 pTX406 Der1 -499/+728 (R17LN73L) this study 
pMM043 pTX227 Der1 (R17LC23L) this study 
pMM044 pTX227 Der1 (R17LN73L) this study 
pMM046 pTX227 Der1 (K50A) this study 
pMM047 pTX227 Der1 (R55A) this study 
pMM048 pTX227 Der1 (Y58L) this study 
pMM049 pTX227 Der1 (Q52A) this study 
pMM052 pTX227 Der1 (S77L) this study 
pMM053 pTX227 Der1 (S59L) this study 
pMM054 pTX227 Der1 (P37A) this study 
pMM055 pTX227 Der1 (G38W) this study 
pMM056 pTX227 Der1 (D45A) this study 
pMM057 pTX227 Der1 (L46A) this study 
pMM058 pTX227 Der1 (K49A) this study 
pMM063 pRS425-CUP Der1 this study 
pMM064 pRS416 Der1 -500/+636-1xHA this study 
pMM074 pRS425-CUP Der1 -500/+706 (R17LN73L)-13xMyc this study 
pMM075 pRS425-CUP Der1 -499/+706-13xMyc this study 
pMM076 pRS413 PrA*-3xHA this study 
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